Terms of Use

  • PRO-CTCAE is freely available for all to use in their clinical trials, and we encourage and facilitate this use! No permission is required.
  • To protect the integrity of PRO-CTCAE, the US National Cancer Institute holds all rights and title to PRO-CTCAE, all translations, and related documents.
  • To assure standardized translations, users are not permitted to translate PRO-CTCAE without a prior written agreement with the National Cancer Institute.

Terms of Use

Thank you for your interest in using NCI's PRO-CTCAE™(version 1.0) in your clinical trial.

Definitions

  • 'Provider': the National Cancer Institute
  • 'Recipient': the party who receives PRO-CTCAE™ from the Provider under this agreement
  • 'PRO-CTCAE™': questions selected by the Recipient from the items in the PRO-CTCAE item library version 1.0 created by Provider

Terms of Use

  1. Recipient agrees that use of PRO-CTCAE is limited to describing in aggregate the safety and tolerability of a therapeutic compound or device, and does not include the use of PRO-CTCAE for diagnostic, prognostic or therapeutic purposes in human subjects and does not include use of PRO-CTCAE to assess the efficacy of medical drugs or devices.
  2. Recipient agrees not to adapt, alter, amend, abridge, modify, condense, make derivative works, or translate PRO-CTCAE without prior written consent from the Provider.
  3. Recipient shall not reproduce PRO-CTCAE except as is necessary for conducting the study. Recipient shall not distribute, publish, sell, license, or provide by any means whatsoever to third parties not involved with the study copies of PRO-CTCAE without the prior written agreement of the Provider.
  4. Recipient agrees and undertakes not to sell or incorporate PRO-CTCAE into materials that could be sold with the exception of educational materials, such as printed books and journals.
  5. In case of any kind of presentation or publication reporting PRO-CTCAE results, Recipient shall include a reference to the PRO-CTCAE website (https://healthcaredelivery.cancer.gov/pro-ctcae/).
  6. Recipient will include Provider's trademark ownership statement on all copies of the PRO-CTCAE in the same form as it appears on the document that Recipient is downloading from this website.
  7. Recipient agrees and undertakes to comply with all applicable laws and regulations applicable to research studies and the handling of research materials, including those governing human subjects protections, as well as good research practices, in connection with the use of PRO-CTCAE, and to give prompt notice to the Provider if, at any time Recipient is advised by any authority that their use of PRO-CTCAE is not in accordance with all applicable laws, regulations or good research practices.
  8. Recipient agrees and undertakes to indemnify and hold Provider harmless against any and all claims, loss or damage, including fees, penalties or fines and third party claims, and attorneys' fees arising from Recipient's use of PRO-CTCAE.
  9. Consent to Recipient's use of PRO-CTCAE under these Terms and Conditions is given 'AS IS', without any accompanying services or improvements. Provider does not accept any liability resulting from Recipient's use of PRO-CTCAE.
  10. PRO-CTCAE is supplied to recipient with no warranties or representations of any kind as to the accuracy, currency, or completeness of the information accessed and used through this website, or the fitness of PRO-CTCAE for a particular purpose. Neither provider nor any party involved in creating, producing, or delivering PRO-CTCAE shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect, or punitive damages arising out of access to, use of or inability to use PRO-CTCAE, or any errors or omissions in the content theoreof.
  11. Should Recipient desire to use PRO-CTCAE in a manner not permitted under these Terms and Conditions, please e-mail NCIPROCTCAEInquiries@mail.nih.gov.